First-in-Class KRAS-Degrader Promising in Pancreatic, Lung Cancers

(MedPage Today) — Setidegrasib showed promising efficacy in patients with previously treated KRAS G12D-mutated advanced pancreatic ductal adenocarcinoma (PDAC) or non-small cell lung cancer (NSCLC), phase I trial results suggest. Among…